A Study of Long-Term Responders on Olaparib
(OLALA Trial)

Recruiting in Palo Alto (17 mi)

+7 other locations

Overseen ByAmit Oza, M.D.

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University Health Network, Toronto

No Placebo Group

Approved in 2 jurisdictions

Trial Summary

What is the purpose of this trial?This is an observational and sample collection study involving patients (alive or deceased) from several clinical trials who had received the investigational drug, olaparib in other research studies. There is no intervention given for this study. This research is being done to understand of the mechanisms involved in patients whose cancer responds well and whose cancer does not respond well to investigational drug, olaparib, to help better understand how olaparib works and to better identify patients who may benefit from this therapy.

Eligibility Criteria

Inclusion Criteria

single agent olaparib given for relapsed disease or single agent olaparib given as maintenance therapy after response to platinum based chemotherapy or olaparib combined with platinum based chemotherapy and then continued as maintenance therapy or olaparib combined with other types of therapy

Had a durable response to Olaparib defined as patients who have benefited from olaparib for > 18 months. Patients who discontinued Olaparib due to toxicities but otherwise meet the definition of a durable response will be included or the control group is patients who had a short duration benefit with Olaparib of less than 6 months in any individual clinical trial/standard of care

Ability to understand and the willingness to sign a written informed consent document.

+1 more